Document Type : Original articles


1 Department of Biochemistry, University of Anbar College of Medicine, Ramadi City, Anbar, 31001, Iraq

2 Department of Chemistry, College of Medicine, University of Basrah, Basrah, Iraq.

3 Depart of Biochemistry, College of Medicine, University of Basrah, Basrah, Iraq


Background: Hypothyroidism is one of the mostimportant thyroid disorders, and chronic autoimmune (Hashimoto's) thyroiditis is the most common cause in iodine-replete areas. Anti-thyroglobulin antibodies (anti-Tg Ab) and anti-thyroid peroxidase antibodies (anti-TPO Ab) are commonly associated with the development of chronic autoimmune thyroiditis. However, the precise relationship between them has not been defined yet.
Objective: To study the relationship between anti-Tg Ab and anti-TPO Ab among patients with primary hypothyroidism.
Materials and Methods: In a cross-sectional study of 169 patients with primary hypothyroidism, their anti-TPO Ab and anti-Tg Ab were measured, analyzed, and correlated together.
Results: Positive anti-TPO Ab and anti-Tg Ab were observed in 52.1% of the patients, while 26% and 8.9% of them were only positive for anti-TPO Ab or anti-Tg Ab, respectively, and the remaining 13% showed no positivity for both of them. Anti-Tg Ab titer increased steadily with advancing age in contrast to anti-TPO Ab (P-value = 0.009). The best and highest positive predictive value for having a positive anti-TPO Ab was 91%, and this was obtained at an anti-Tg titer of > 691 IU/mL with a sensitivity of 31% and specificity of 89% at an odds ratio of 3.72 (P-value = 0.014). The best negative predictive value was seen at an anti-Tg Ab titer < 11 IU/mL with a sensitivity of 99% and a specificity of 24% (P-value < 0.001), while a maximum Youden’s value of 1.4 (i.e., maximum sensitivity at a maximum specificity) was obtained at a titer of 26 IU/mL with a positive predictive value of 86% and a negative predictive value of 59% with a sensitivity of 90% and a specificity of 51% (P-value < 0.001).
Conclusion: Both anti-Tg Ab and anti-TPO Ab had considerable information in patients with chronic autoimmune hypothyroidism. Anti-Tg Ab tends to be more informative in older people (> 50 years), where  it is more prevalent than anti-TPO Ab. At an anti-Tg Ab titer > 691 IU/mL, we most likely will have positive anti-TPO Ab, while at an anti-Tg Ab titer < 11 IU/ml, we most likely have negative anti-TPO Ab.


Main Subjects

[1]      L. Chiovato, F. Magri, and A. Carlé, “Hypothyroidism in context: where we’ve been and where we’re going,” Adv. Ther., vol. 36, pp. 47–58, 2019.
[2]      Y. Aoki, R. M. Belin, R. Clickner, R. Jeffries, L. Phillips, and K. R. Mahaffey, “Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999–2002),” Thyroid, vol. 17, no. 12, pp. 1211–1223, 2007.
[3]      A. Garmendia Madariaga, S. Santos Palacios, F. Guillén-Grima, and J. C. Galofré, “The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis,” J. Clin. Endocrinol. Metab., vol. 99, no. 3, pp. 923–931, 2014.
[4]      B. Zaman et al., “Prevalence of thyroid dysfunctions in a large, unselected population in Duhok city, Iraqi Kurdistan: A cross-sectional study,” J. Biol. Res. della Soc. Ital. di Biol. Sper., vol. 94, no. 2, 2021.
[5]      U. Feldt-Rasmussen, G. Effraimidis, and M. Klose, “The hypothalamus-pituitary-thyroid (HPT)-axis and its role in physiology and pathophysiology of other hypothalamus-pituitary functions,” Mol. Cell. Endocrinol., vol. 525, p. 111173, 2021.
[6]      S. Ferraro et al., “Reference intervals for thyroid biomarkers to enhance the assessment of thyroid status in childhood and adolescence,” Clin. Chem. Lab. Med., 61(7):1309-1318, 2023.
[7]      N. Sawicka-Gutaj, D. Wietrzyk, N. Zawalna, A. Erampamoorthy, and M. Ruchała, “Autoimmune disorders and thyroid function in patients with rheumatoid arthritis after biological treatment,” in Rheumatology Forum, vol. 8, no. 3, pp. 111–121, 2022.
[8]      B. Rapoport and S. McLachlan, “Half a century after the discovery of thyroid autoimmunity: the impact of molecular biology.,” Thyroid Off. J. Am. Thyroid Assoc., vol. 17, no. 10, pp. 909–910, 2007.
[9]      T. Diana, K. A. Ponto, and G. J. Kahaly, “Thyrotropin receptor antibodies and Graves’ orbitopathy,” J. Endocrinol. Invest., vol. 44, pp. 703–712, 2021.
[10]    E. Machała, M. Redynk, I. Iavorska, and P. Machała, “Hashimoto’s thyroiditis,” World Sci. News, vol. 128, no. 2, pp. 302–314, 2019.
[11]    E. Alinia-Ahandani et al., “Assessment of the Relation of Anti-TPO and TSH, T3 and T4 Levels between Some Subclinical Diabetes Patients in Iran,” J. Pharm. Res. Int., vol. 34, no. 31A, pp. 16–25, 2022.
[12]    B. Czarnocka, D. C. Eschler, M. Godlewska, and Y. Tomer, “Thyroid autoantibodies: thyroid peroxidase and thyroglobulin antibodies,” in Autoantibodies, Elsevier, pp. 365–373, 2014.
[13]    T. Siriwardhane et al., “Significance of anti-TPO as an early predictive marker in thyroid disease,” Autoimmune Dis., vol. 2019, 2019.
[14]    E. Fröhlich and R. Wahl, “Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases,” Front. Immunol., vol. 8, p. 521, 2017.
[15]    R. A. Nordyke, F. I. Gilbert, L. A. Miyamoto, and K. A. Fleury, “The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto’s thyroiditis,” Arch. Intern. Med., vol. 153, no. 7, pp. 862–865, 1993.
[16]    H. Jg, “Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III),” J Clin Endocrinol Metab, vol. 87, pp. 489–499, 2002.
[17]    P. Kocełak et al., “Anti-thyroid antibodies in the relation to TSH levels and family history of thyroid diseases in young Caucasian women,” Front. Endocrinol. (Lausanne)., vol. 13, p. 1081157, 2022.
[18]    A. Aminorroaya, R. Meamar, M. Amini, A. Feizi, A. Tabatabae, and E. Faghih Imani, “Incidence of thyroid dysfunction in an Iranian adult population: the predictor role of thyroid autoantibodies: results from a prospective population-based cohort study,” Eur. J. Med. Res., vol. 22, no. 1, pp. 1–10, 2017.
[19]    M. P. J. Vanderpump et al., “The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey,” Clin. Endocrinol. (Oxf)., vol. 43, no. 1, pp. 55–68, 1995.
[20]    C. T. Sawin, W. P. Castelli, J. M. Hershman, P. McNamara, and P. Bacharach, “The aging thyroid: thyroid deficiency in the Framingham study,” Arch. Intern. Med., vol. 145, no. 8, pp. 1386–1388, 1985.
[21]    M. A. Hannan et al., “Hypothyroidism in Bangladesh: Is Autoimmunity the Next Big Threat?,” Mymensingh Med. J. MMJ, vol. 31, no. 2, pp. 449–457, 2022.
[22]    E. Nishihara et al., “Comparison of thyroglobulin and thyroid peroxidase antibodies measured by five different kits in autoimmune thyroid diseases,” Endocr. J., vol. 64, no. 10, pp. 955–961, 2017.
[23]    Y. Li et al., “Dynamic changes in antithyroperoxidase and antithyroglobulin antibodies suggest an increased risk for abnormal thyrotropin levels,” Front. Endocrinol. (Lausanne)., vol. 11, p. 521, 2020.
[24]    P. Saravanan and C. M. Dayan, “Thyroid autoantibodies,” Endocrinol. Metab. Clin. North Am., vol. 30, no. 2, pp. 315–337, 2001.
[25]    T. Komaki et al., “Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves’ disease during long-term treatment period,” Nihon Naibunpi Gakkai Zasshi, vol. 65, no. 7, pp. 627–639, 1989.
[26]    T. ARAI, C. KURASHIMA, M. UTSUYAMA, M. SAWABE, and H. ITO, “Measurement of Anti-Thyroglobulin and Anti-Thyroid Peroxidase Antibodies Using Highly Sensitive Radioimmunoassay An Effective Method for Detecting Asymptomatic Focal Lymphocytic Thyroiditis in the Elderly,” Endocr. J., vol. 47, no. 5, pp. 575–582, 2000.
[27]    M. Sulejmanovic, A. Begić, F. Mujaric-Bousbia, S. Salkic, and A. Ramas, “The relationship between thyroid antibodies and vitamin D level in primary hypothyroidism,” Med. Arch., vol. 74, no. 5, p. 359, 2020.
[28]    K. Kasagi et al., “Clinical significance of measurements of antithyroid antibodies in the diagnosis of Hashimoto’s thyroiditis: comparison with histological findings,” Thyroid, vol. 6, no. 5, pp. 445–450, 1996.
[29]    I. Guldvog et al., “Thyroidectomy versus medical management for euthyroid patients with Hashimoto disease and persisting symptoms: a randomized trial,” Ann. Intern. Med., vol. 170, no. 7, pp. 453–464, 2019.
[30]    J. Chaudhuri, A. Mukherjee, and A. Chakravarty, “Hashimoto’s encephalopathy: case series and literature review,” Curr. Neurol. Neurosci. Rep., vol. 23, no. 4, pp. 167–175, 2023.